San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, Oncternal Therapeutics is raising $3,456,308.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, James Breitmeyer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Oncternal Therapeutics

Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. We’re committed to translate pioneering areas of cancer research into approved therapies that can be used to treat multiple cancer types. With an eternal focus on oncology, we are committed to advancing our pipeline of potential first-in-class therapies to create a new wave of better treatments for cancer.

To learn more about Oncternal Therapeutics, visit http://www.oncternal.com/

Contact:
James Breitmeyer, President and Chief Executive Officer
858-434-1113
jbreitmeyer@oncternal.com
https://www.linkedin.com/in/jim-breitmeyer-6b79a314/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved